Health
Dapagliflozin Misses Early Mark in COVID-19, but Kosiborod Sees Reasons for More Study – AJMC.com Managed Markets Network
The Dapagliflozin in Respiratory Failure in Patients With COVID-19 trial is the first phase 3 study to examine whether this SGLT2 inhibitor, which has proven effective…
A study that misses its mark would not typically generate this much interest, especially after trial sponsor AstraZeneca announced last month that results fell short of statistical significance. But with SGTL2 inhibitors gaining indications in heart failure and CKD, along with their original T2D approvalsconditions that put patients in danger when they get COVID-19many suspect this weekends results will not be the last word.
Since Kosiborod is one of the worlds leading experts on SGLT2 inhibitors,…
-
General13 hours agoPolice investigating after body found on road in Newborough, Gippsland
-
Noosa News5 hours agoWhy the Brisbane City Hall clock has fallen silent
-
Noosa News17 hours agoNew One Nation branch | Noosa Today
-
Noosa News7 hours agoFederal government to review trade restrictions for Philippine banana imports